Hero

Celyad Reports First Half 2016 Financial Results and Operational Progress

1

Celyad Reports First Half 2016 Financial Results and Operational Progress

Developing breakthrough pioneering therapies for life-threatening diseases

2

Developing breakthrough pioneering therapies for life-threatening diseases

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

3

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD

4

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD

About Celyad

Driven by a passion to invent

Celyad is a clinical-stage biopharmaceutical company focused on the discovery and development of breakthrough pioneering cell-based therapies for life-threatening diseases.

More info about Celyad

Latest News

Celyad Letter for Shareholders

Celyad Letter for Shareholders

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad Reports First Half 2016 Financial Results and Operational Progress

Discover all news

Social Feed

Watch Prof. Jozef Bartunek's #CHART1 results outline presentation at #ESC2016 https://t.co/RzYO32zxkj #heartfailure (upon subscription)

3 hours ago

Watch Prof. Jozef Bartunek's #CHART1 results outline presentation at #ESC2016 https://t.co/RzYO32zxkj #heartfailure (upon subscription)

Presentation of Prof. Philippe Menasche zt #ESC2016 https://t.co/MVCSmBITQC #CHART1 #heartfailure #celltherapy (upon subscription)

3 hours ago

Presentation of Prof. Philippe Menasche zt #ESC2016 https://t.co/MVCSmBITQC #CHART1 #heartfailure #celltherapy (upon subscription)

CHART-1 Results Outline Presentation by Prof. Jozef Bartunek - ESC2016

3 hours ago

CHART-1 Results Outline Presentation by Prof. Jozef Bartunek - ESC2016

Presentation of Prof. Philippe Menasche at ESC Congress 2016

3 hours ago

Presentation of Prof. Philippe Menasche at ESC Congress 2016

Watch Prof. Jozef Bartunek's #CHART1 results outline presentation at #ESC2016 https://t.co/RzYO32zxkj #heartfailure (upon subscription)

3 hours ago

Watch Prof. Jozef Bartunek's #CHART1 results outline presentation at #ESC2016 https://t.co/RzYO32zxkj #heartfailure (upon subscription)

Presentation of Prof. Philippe Menasche zt #ESC2016 https://t.co/MVCSmBITQC #CHART1 #heartfailure #celltherapy (upon subscription)

3 hours ago

Presentation of Prof. Philippe Menasche zt #ESC2016 https://t.co/MVCSmBITQC #CHART1 #heartfailure #celltherapy (upon subscription)

RT @escardio: #CHART-1 tested efficacy of #cardiopoietic cells in advanced ischaemic #heartfailure - Jozef Bartunek #ESCcongress

23 hours ago

RT @escardio: #CHART-1 tested efficacy of #cardiopoietic cells in advanced ischaemic #heartfailure - Jozef Bartunek #ESCcongress

RT @escardio: #CHART-1 suggests #cardiopoietic cells may benefit patients with larger ventricles and fewer injections - Jozef Bartunek #ESC…

23 hours ago

RT @escardio: #CHART-1 suggests #cardiopoietic cells may benefit patients with larger ventricles and fewer injections - Jozef Bartunek #ESC…

CHART-1 Results Outline Presentation by Prof. Jozef Bartunek - ESC2016

3 hours ago

CHART-1 Results Outline Presentation by Prof. Jozef Bartunek - ESC2016

Presentation of Prof. Philippe Menasche at ESC Congress 2016

3 hours ago

Presentation of Prof. Philippe Menasche at ESC Congress 2016

CHART-1 Largest Cardiac Regenerative Therapy Trial Brings New Insights

23 hours ago

CHART-1 Largest Cardiac Regenerative Therapy Trial Brings New Insights

Celyad Reports First Half 2016 Financial Results and Operational Progress

4 days ago

Celyad Reports First Half 2016 Financial Results and Operational Progress